Effects of Intravenous Terbutaline on Maternal Circulation and Fetal Heart Activity

1990 ◽  
Vol 69 (3) ◽  
pp. 223-228 ◽  
Author(s):  
Anders Cson Roth ◽  
Ian Milsom ◽  
Lars Forssman ◽  
Lars-Goran Ekman ◽  
Thomas Hedner
Author(s):  
R. Schats ◽  
G. Brandsma ◽  
L.M. Cleveringa ◽  
P.F.C. Lankhorst ◽  
I.S. Vroegop ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Paul Singh ◽  
Tara Swanson

Introduction.Fetomaternal hemorrhage represents a transfer of fetal blood to the maternal circulation. Although many etiologies have been described, most causes of fetomaternal hemorrhage remain unidentified. The differentiation between acute and chronic fetomaternal hemorrhage may be accomplished antenatally and may influence perinatal management.Case.A 36-year-old gravida 6 para 3 presented at 37 and 5/7 completed gestational weeks with ultrasound findings suggestive of chronic fetal anemia such as right ventricular enlargement, diminished cerebral vascular resistance, and elevated middle cerebral artery end-diastolic velocity. On the other hand, signs of acute fetal decompensation such as deterioration of the fetal heart tracing, diminished biophysical score, decreased cord pH, and increased cord base deficit were noted. Following delivery, the neonate’s initial hemoglobin was 4.0 g/dL and the maternal KB ratio was 0.015 indicative of a significant fetomaternal hemorrhage.Discussion.One should consider FMH as part of the differential diagnosis for fetal or immediate neonatal anemia. We describe a unique case of FMH that demonstrated both acute and chronic clinical features. It is our hope that this case will assist practitioners in differentiating acute FMH that may require emergent delivery from chronic FMH which may be able to be expectantly managed.


2019 ◽  
Vol 78 (3) ◽  
pp. 269-279
Author(s):  
O. Viunytskyi ◽  
V. I. Shulgin ◽  
A. V. Totsky ◽  
Karen O. Egiazarian ◽  
O. A. Polotska

2003 ◽  
Vol 81 (3) ◽  
pp. 263-266 ◽  
Author(s):  
Y. Tannirandorn ◽  
S. Sangsawang ◽  
S. Manotaya ◽  
B. Uerpairojkit ◽  
P. Samritpradit ◽  
...  

2002 ◽  
Vol 78 ◽  
pp. S250
Author(s):  
Kwang Moon Yang ◽  
Jin Hyun Jun ◽  
In Ok Song ◽  
Jin Yeong Kim ◽  
Jong Young Jun ◽  
...  

2020 ◽  
Vol 16 ◽  
Author(s):  
Nafiseh Saghafi ◽  
Leila Pourali ◽  
Atiyeh Vatanchi ◽  
Zahra Rastin

Background : Cesarean scar pregnancy (CSP) is the implantation of the gestational sac in the hysterotomy scar. The optimal treatment for a cesarean scar pregnancy is unclear and therapy should be selected according to the patients' clinical presentation. The aim of this study was reporting a successful medical treatment of a cesarean scar pregnancy with fetal heart activity and a very high level of beta human chorionic gonadotropin (β-hCG). Case Presentation: A 38-year-old woman referred for routine prenatal visit after 2 months of menstrual retard and positive pregnancy test. She had the history of 3 cesarean sections and a uterine curettage. Untrasonography revealed cesarean scar ectopic pregnancy. The serum level of β-hCG was 109063 mIU/ml. Two doses of systemic methotrexate therapy and intragestational sac injection of methotrexate and potassium chloride were administered. 8 weeks after the initial treatment, β-hCG level became undetectable. Conclusion: Combined medical treatment with local and systemic MTX administration may be a successful treatment with low complication even in the presence of high serum β-hCG level.


2015 ◽  
Vol 2015 ◽  
pp. 1-3
Author(s):  
Rodney McLaren ◽  
Sandra McCalla ◽  
Mohamad Irani

Cesarean scar ectopic pregnancy (CSP) is a rare type of ectopic pregnancy that is growing in incidence. The diagnosis of most CSP occurs when patients present in unstable conditions requiring surgical management and leading sometimes to hysterectomy. It has been shown that medical management is a safe option for early diagnosed hemodynamically stable CSP. However, no cases of CSP withβ-hCG higher than 62,000 IU/L, conservatively treated, have been reported. We report the case of a 29-year-old patient who presented for her first prenatal visit at 13-week gestation and was diagnosed with CSP with present fetal heart tones and a quantitativeβ-hCG of 144,337 IU/L. She was treated with bilateral uterine artery embolization and systemic methotrexate. Herβ-hCG significantly decreased and became undetectable within 10 weeks. We propose that patients with CSP with very highβ-hCG and fetal heart activity can be offered conservative or fertility preserving management.


Sign in / Sign up

Export Citation Format

Share Document